Expediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patients

PAGE 33 (2025) Abstr 11445
Glatard A, Mezzalana E, Zheng M, Bergstrand M, Smania G.
ConferenceMIDDOncologyPhase IIIProgram strategies and efficienciesRegulatory interactions

Pharmetheus Affiliates

Portrait-of-Anais-Glatard_Pharmetheus
Senior Director, MIDD Consultant

Anaïs Glatard

See bio
Portrait-of-Enrica-Mezzalana_Pharmetheus-1
Senior Director, MIDD Consultant

Enrica Mezzalana

See bio
Portrait-of-Martin-Bergstrand_Pharmetheus
Principal Director, MIDD Scientific Lead

Martin Bergstrand

See bio
Portrait-of-Giovanni-Smania-Pharmetheus
Principal Director, MIDD Consultant

Giovanni Smania

See bio